Inefficacy of Immunosuppressive Therapy for Severe Aplastic Anemia Progressing From Non-SAA: Improved Outcome After Allogeneic Hematopoietic Stem Cell Transplantation

被引:3
|
作者
Liu, Limin [1 ]
Zhao, Xin [2 ]
Miao, Miao [1 ]
Zhang, Yanming [3 ,4 ]
Jiao, Wenjing [5 ]
Lei, Meiqing [6 ]
Zhou, Huifen [1 ]
Wang, Qingyuan [1 ]
Cai, Yifeng [7 ]
Zhao, Liyun [8 ]
Shangguan, Xiaohui [9 ]
Liu, Zefa [10 ]
Xu, Jinge [11 ]
Zhang, Fengkui [2 ]
Wu, Depei [1 ]
机构
[1] Soochow Univ, Natl Clin Res Ctr Hematol Dis, Jiangsu Inst Hematol, Affiliated Hosp 1, Suzhou, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Expt Hematol, Natl Clin Res Ctr Blood Dis, Anemia Therapeut Ctr,Inst Hematol & Blood Dis Hos, Tianjin, Peoples R China
[3] Xuzhou Med Univ, Dept Hematol, Affiliated Huaian Hosp, Huaian, Peoples R China
[4] Second Peoples Hosp Huaian, Huaian, Peoples R China
[5] Xian Yang Cent Hosp, Dept Hematol, Xianyang, Peoples R China
[6] Cent South Univ, Dept Hematol, Haikou Municipal Peoples Hosp, Affiliated Haikou Hosp,Xiangya Sch Med, Haikou, Hainan, Peoples R China
[7] Nantong Univ, Dept Hematol, Affiliated Hosp, Nantong, Peoples R China
[8] People Hosp Xingtai, Dept Hematol, Xingtai, Peoples R China
[9] Fujian Med Univ, Dept Hematol, Longyan Hosp 1, Longyan, Peoples R China
[10] People Hosp Xinghua, Dept Hematol, Xinghua, Peoples R China
[11] Xuzhou Med Univ, Dept Hematol, Affiliated Hosp 2, Xuzhou, Jiangsu, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2021年 / 11卷
基金
国家重点研发计划;
关键词
severe aplastic anemia; immunosuppressive therapy; hematopoietic stem cell transplantation; first-line therapy; outcome; BONE-MARROW-TRANSPLANTATION; HIGH-DOSE CYCLOPHOSPHAMIDE; ANTI-THYMOCYTE GLOBULIN; ANTITHYMOCYTE GLOBULIN; POSTTRANSPLANTATION CYCLOPHOSPHAMIDE; CYCLOSPORINE; GUIDELINES; MANAGEMENT; DIAGNOSIS; CHILDREN;
D O I
10.3389/fonc.2021.739561
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and Aims This study aimed at comparing the efficacy and safety of severe aplastic anemia (SAA) cases that had met the criteria for SAA at the time of diagnosis (group A) with SAA that had progressed from non-SAA (NSAA) (group B), both undergoing first-line immunosuppressive therapy (IST). Additionally, group B was compared with SAA that had progressed from NSAA and who had been treated by allogeneic hematopoietic stem cell transplantation (allo-HSCT) (group C).</p> Methods We retrospectively compared 608 consecutive patients in group A (n = 232), group B (n = 229) and group C (n = 147) between June 2002 and December 2019. Six months after treatment, the rate of overall response and the fraction of patients who had achieved normal blood values, treatment-related mortality (TRM), secondary clonal disease, 5-year overall survival (OS) and failure-free survival (FFS) were indirectly compared between group A and group B, group B and group C.</p> Results Six months after treatment, the rate of overall response and the fraction of patients who had achieved normal blood values in group A was higher than in group B (65.24% vs. 40.54%, P < 0.0001; 23.33% vs. 2.25%, P < 0.0001); the same was true for group C (92.50% vs. 2.25%, P < 0.0001). The rate of relapse in group B was higher than in group C (P < 0.0001), but there were no differences in TRM and secondary clonal disease (P > 0.05). There were no differences in estimated 5-year OS between groups A and B (83.8% +/- 2.6% vs. 85.8% +/- 2.6%, P = 0.837), or between B and C (85.8% +/- 2.6% vs. 77.9% +/- 3.4%, P = 0.051). The estimated 5-year FFS in groups A and C was higher than for group B (57.1% +/- 3.3% vs. 39.7% +/- 3.4%, P < 0.001; 76.7% +/- 3.5% vs. 39.7% +/- 3.4%, P < 0.0001).</p> Conclusion These results indicate that IST is less effective in SAA progressing from non-SAA but allo-HSCT can improve outcomes.</p>
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Conditional survival and standardized mortality ratios of patients with severe aplastic anemia surviving at least one year after hematopoietic cell transplantation or immunosuppressive therapy
    Nakamura, Ryotaro
    Patel, Bhavisha A.
    Kim, Soyoung
    Wong, F. Lennie
    Armenian, Saro H.
    Groarke, Emma M.
    Keesler, Daniel
    Hebert, Kyle M.
    Heim, Michael
    Eapen, Mary
    Young, Neal S.
    HAEMATOLOGICA, 2023, 108 (12) : 3298 - 3307
  • [42] Severe aplastic anemia patients with infection who received an allogeneic hematopoietic stem cell transplantation had a better chance: Long-term outcomes of a multicenter study
    Liu, Limin
    Miao, Miao
    He, Hailong
    Wang, Shunqing
    Zhang, Yanming
    Guo, Ailian
    Jiao, Wenjing
    Lei, Meiqing
    Cai, Yifeng
    Shangguan, Xiaohui
    Liu, Zefa
    Xu, Jinge
    Li, Xiaoli
    Zhang, Liansheng
    Wu, Depei
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [43] Transformation of Severe Aplastic Anemia into Donor Cell Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: A Rare Case Report
    Wang, Qianqian
    Xu, Hong
    Yu, Wei
    Sun, Lingjie
    Zhao, Hongguo
    Shi, Xue
    Shi, Xue
    AMERICAN JOURNAL OF CASE REPORTS, 2024, 25
  • [44] Immunosuppressive therapy versus alternative donor hematopoietic stem cell transplantation for children with severe aplastic anemia who lack an HLA-matched familial donor
    Choi, Y. B.
    Yi, E. S.
    Lee, J. W.
    Sung, K. W.
    Koo, H. H.
    Yoo, K. H.
    BONE MARROW TRANSPLANTATION, 2017, 52 (01) : 47 - 52
  • [45] Conditional survival and standardized mortality ratios of patients with severe aplastic anemia surviving at least one year after hematopoietic cell transplantation or immunosuppressive therapy
    Nakamura, Ryotaro
    Patel, Bhavisha A.
    Kim, Soyoung
    Wong, F. Lennie
    Armenian, Saro H.
    Groarke, Emma M.
    Keesler, Daniel
    Hebert, Kyle M.
    Heim, Michael
    Eapen, Mary
    Young, Neal S.
    REVISTA CHILENA DE LITERATURA, 2023, (108): : 3298 - 3307
  • [46] Combined use of Chinese medicine with allogeneic hematopoietic stem cell transplantation for severe aplastic anemia patients
    Ye Bao-dong
    Zhang Xiang
    Shao Ke-ding
    Chen Dan
    Zhang Yu
    Wu Di-jiong
    Yu Qing-hong
    Shen Jian-ping
    Shen Yi-ping
    Zhou Yu-hong
    CHINESE JOURNAL OF INTEGRATIVE MEDICINE, 2014, 20 (12) : 903 - 909
  • [47] Influence of donor/recipient sex matching on outcome of allogeneic hematopoietic stem cell transplantation for aplastic anemia
    Stern, Martin
    Passweg, Jakob R.
    Locasciulli, Anna
    Socie, Gerard
    Schrezenmeier, Hubert
    Bekassy, Albert N.
    Fuehrer, Monica
    Hows, Jill
    Korthof, Elisabeth T.
    McCann, Shaun
    Tichelli, Andre
    Zoumbos, Nicholas C.
    Marsh, Judith C. W.
    Bacigalupo, Andrea
    Gratwohl, Alois
    TRANSPLANTATION, 2006, 82 (02) : 218 - 226
  • [48] Impact of pretransplant red cell transfusion on outcome after allogeneic stem cell transplantation in adult patients with severe aplastic anemia
    Lee, S-E
    Yahng, S-A
    Cho, B-S
    Eom, K-S
    Kim, Y-J
    Kim, H-J
    Min, C-K
    Lee, S.
    Cho, S-G
    Kim, D-W
    Min, W-S
    Lee, J. W.
    BONE MARROW TRANSPLANTATION, 2016, 51 (10) : 1323 - 1329
  • [49] Effect of race on outcomes after allogeneic hematopoietic cell transplantation for severe aplastic anemia
    Eckrich, Michael J.
    Ahn, Kwang-Woo
    Champlin, Richard E.
    Coccia, Peter
    Godder, Kamar
    Horan, John
    Margolis, David
    Deeg, H. Joachim
    Eapen, Mary
    AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (02) : 125 - 129
  • [50] Analysis of allogeneic hematopoietic stem cell transplantation with high-dose cyclophosphamide-induced immune tolerance for severe aplastic anemia
    Guo, Zhi
    Gao, Hong-yan
    Zhang, Tian-yan
    Liu, Xiao-dong
    Yang, Kai
    Lou, Jing-xing
    He, Xue-peng
    Zhang, Yuan
    Chen, Peng
    Chen, Hui-ren
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2016, 104 (06) : 720 - 728